Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs Academic Article uri icon

Overview

MeSH Major

  • Aminopyridines
  • Antineoplastic Combined Chemotherapy Protocols
  • Macrophages
  • Neurilemmoma
  • Proto-Oncogene Proteins c-kit
  • Pyrroles
  • Receptor, Platelet-Derived Growth Factor beta

abstract

  • Taken together, our data strongly suggest that PLX3397 is superior to imatinib in the treatment of MPNSTs, and the combination of PLX3397 with a TORC1 inhibitor could provide a new therapeutic approach for the treatment of this disease.

publication date

  • June 15, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4060793

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-2576

PubMed ID

  • 24718867

Additional Document Info

start page

  • 3146

end page

  • 58

volume

  • 20

number

  • 12